Cosibelimab Shows Sustained Results in Advanced CSCC at 2.5 Years
Updated pivotal data on cosibelimab, an anti-PD-L1 antibody, in locally advanced and metastatic CSCC show results with a median follow-up of at least 2.5 years, per ESMO 2026 presentation.